ResponderID™ KRAS: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapeutics
Traditional biomarkers often fail to capture the dynamic nature [...]
Evaluation of a KRAS gene expression signature in lung cancer
This study evaluates the efficacy of a KRAS gene [...]
The Xerna™ TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment
This poster illustrates the potential of the Xerna™ TME [...]
ResponderID™: The Biology-First Machine Learning Platform for Biomarker Discovery
Rarely has a complex gene signature been successfully translated [...]
Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients
This study investigates the potential of the Xerna™ TME [...]
Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA assay
This study evaluates the efficacy of maintenance durvalumab in [...]
Xerna™ TME Panel: A pan-cancer RNA-based investigational assay designed to predict patient response to angiogenic- and immune-targeted therapies
The Xerna™ TME Panel is a pan-cancer RNA-based investigational [...]
RNA-Based Diagnostic Panel Matches TME Phenotype to Therapeutic Mechanism of Action in Colorectal Cancer
The study introduces TME Panel-1, an RNA-based diagnostic panel [...]
Development of an RNA-based Diagnostic Platform Based on the Tumor Microenvironment Dominant Biology
The study presents the development of an RNA-based diagnostic [...]
